Dendrimer-Based Nanotherapeutics

Dr. Prashant Kesharwani is an assistant professor of pharmaceutics at School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 300 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, most prestigious “Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community.

1. History and introduction of dendrimers2. Properties of dendrimers3. Biological interactions of dendrimers4. Dendrimer nomenclature and synthesis methods5. Types of dendrimers6. Characterization of dendrimers7. Safety and toxicity issues of dendrimers8. Dendrimer-drug conjugate9. PEGylated dendrimer10. Surface engineered dendrimers in targeting and delivery of drugs11. Dendrimer hybrids with other nanocarriers12. Dendrimers for solubility enhancement13. Dendrimers for gene therapy14. Dendrimer for photodynamic therapy15. Dendrimers in tissue engineering16. Dendrimer as imaging contrast agents17. Dendrimer as antimicrobial agents18. Theranostic dendrimer for cancer19. Dendrimer as anti-inflammatory prodrugs20. Advances in targeted dendrimers for cancer therapy and challenges for clinical translation21. Conclusion and future considerations of dendrimers